|
|
|
Insider
Information: |
Mueller Peter |
Relationship: |
Director |
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
2 |
|
Direct
Shares |
311,837 |
|
Indirect Shares
|
25,571 |
|
|
Direct
Value |
$69,562,624 |
|
|
Indirect Value
|
$12,351,816 |
|
|
Total
Shares |
337,408 |
|
|
Total
Value |
$81,914,440 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Vertex Pharmaceuticals Inc |
VRTX |
EVP, Global R&D, CSO |
2014-06-16 |
143,517 |
2014-06-16 |
25,571 |
Premium* |
|
Bioxcel Therapeutics Inc |
BTAI |
Director |
2019-08-23 |
168,320 |
2018-12-04 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
141 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 5 of 6
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2012-09-17 |
4 |
AS |
$57.52 |
$373,880 |
D/D |
(6,500) |
132,316 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2012-10-15 |
4 |
AS |
$52.83 |
$344,015 |
D/D |
(6,500) |
132,316 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2012-10-15 |
4 |
OE |
$16.32 |
$106,080 |
D/D |
6,500 |
138,816 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2013-02-05 |
4 |
A |
$0.01 |
$121 |
D/D |
12,084 |
144,400 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2013-05-16 |
4 |
GD |
$0.00 |
$0 |
I/I |
10,352 |
0 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2013-07-02 |
4 |
AS |
$78.94 |
$9,758,932 |
D/D |
(122,300) |
144,400 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2013-07-02 |
4 |
OE |
$16.32 |
$3,766,911 |
D/D |
122,300 |
266,700 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2013-07-15 |
4 |
OE |
$18.93 |
$141,975 |
D/D |
7,500 |
151,900 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2013-07-15 |
4 |
AS |
$86.17 |
$647,517 |
D/D |
(7,500) |
144,400 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2013-08-15 |
4 |
OE |
$18.93 |
$141,975 |
D/D |
7,500 |
151,900 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2013-08-15 |
4 |
AS |
$77.06 |
$580,560 |
D/D |
(7,500) |
144,400 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2013-09-16 |
4 |
AS |
$76.40 |
$579,160 |
D/D |
(7,500) |
144,400 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2013-09-16 |
4 |
OE |
$18.93 |
$141,975 |
D/D |
7,500 |
151,900 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2013-10-15 |
4 |
OE |
$18.93 |
$141,975 |
D/D |
7,500 |
151,900 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2013-10-15 |
4 |
AS |
$73.19 |
$549,365 |
D/D |
(7,500) |
144,400 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2013-11-15 |
4 |
AS |
$61.58 |
$469,606 |
D/D |
(7,500) |
144,400 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2013-11-15 |
4 |
OE |
$18.93 |
$186,570 |
D/D |
7,500 |
151,900 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2013-12-12 |
4 |
AS |
$65.48 |
$189,892 |
D/D |
(2,900) |
141,500 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2013-12-16 |
4 |
OE |
$28.84 |
$216,300 |
D/D |
7,500 |
149,000 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2013-12-16 |
4 |
AS |
$64.40 |
$485,142 |
D/D |
(7,500) |
141,500 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2014-01-15 |
4 |
OE |
$28.84 |
$216,300 |
D/D |
7,500 |
149,000 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2014-01-15 |
4 |
AS |
$78.67 |
$590,025 |
D/D |
(7,500) |
141,500 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2014-02-05 |
4 |
A |
$0.01 |
$173 |
D/D |
17,250 |
158,750 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2014-02-18 |
4 |
AS |
$82.55 |
$619,442 |
D/D |
(7,500) |
158,750 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2014-02-18 |
4 |
OE |
$28.84 |
$216,300 |
D/D |
7,500 |
166,250 |
0 |
- |
|
141 Records found
|
|
Page 5 of 6 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|